MindWalk Holdings (HYFT) Tax Provisions (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Tax Provisions of $267.73 for Q2 2026, down 68.62% year-over-year from $853.11 in Q2 2025, and down 87.67% quarter-over-quarter from $2171.1 in Q1 2026.
MindWalk Holdings (HYFT) Tax Provisions (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Tax Provisions for 7 consecutive years, with $267.73 the latest figure, recorded in Q2 2026.
- In Q2 2026, Tax Provisions fell 68.62% year-over-year to $267.73; the TTM figure through Apr 2026 stood at $66.2 million (down 86.46% YoY), while the FY2026 annual figure was -$328277.7, up 89.8% from the prior year.
- Tax Provisions fell to $267.73 in Q2 2026 per HYFT's latest filing, from $2171.1 in the prior quarter.
- Across five years, Tax Provisions topped out at $486.4 million in Q3 2024 and bottomed at -$3.1 million in Q2 2024.
- Historically, Tax Provisions has averaged $55.4 million across 5 years, with a median of $129600.9 in 2022.
- Annual changes were most pronounced in 2022 — Tax Provisions plunged 204661.07% — and 2023, when it jumped 141389.63%.
- MindWalk Holdings' Tax Provisions stood at $94864.8 in 2022, then surged by 141389.63% to $134.2 million in 2023, then slumped by 99.6% to $535303.0 in 2024, then sank by 103.37% to -$18022.0 in 2025, then surged by 101.49% to $267.73 in 2026.
- Business Quant data shows HYFT's Tax Provisions at $267.73 in Q2 2026, $2171.1 in Q1 2026, and -$18022.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 267.73 |
| Jan 31, 2026 | 2,171.08 |
| Oct 31, 2025 | -18,021.98 |
| Jul 31, 2025 | 66.23 Mn |
| Apr 30, 2025 | 853.11 |
| Jan 31, 2025 | 2.12 Mn |
| Oct 31, 2024 | 535,303.04 |
| Jul 31, 2024 | 486.39 Mn |
| Apr 30, 2024 | -3.12 Mn |
| Jan 31, 2024 | 575,503.31 |
| Oct 31, 2023 | 134.22 Mn |
| Jul 31, 2023 | 310.92 Mn |
| Apr 30, 2023 | -566,850.72 |
| Jan 31, 2023 | -77,105.02 |
| Oct 31, 2022 | 94,864.82 |
| Jul 31, 2022 | -313,343.43 |
| Apr 30, 2022 | 806,135.79 |
| Jan 31, 2022 | 164,336.98 |
| Oct 31, 2021 | -151.13 |
| Jul 31, 2021 | -153.03 |